{"gene":"EPM2A","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2002,"finding":"Laforin (EPM2A gene product) is a dual-specificity phosphatase; targeted disruption of Epm2a in mice causes formation of Lafora inclusion bodies (positive for ubiquitin and advanced glycation end-products in neurons), widespread neurodegeneration via a non-apoptotic mechanism (swelling of ER, Golgi, mitochondria without apoptotic bodies or DNA fragmentation), ataxia, spontaneous myoclonic seizures, and EEG epileptiform activity.","method":"Epm2a knockout mouse model (gene targeting), histopathology, EEG, behavioral testing","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout mouse with multiple orthogonal phenotypic readouts (histology, EEG, behavior), replicated across tissues","pmids":["12019206"],"is_preprint":false},{"year":2002,"finding":"Laforin contains two functional domains: a carbohydrate-binding domain (CBD, exon 1) and a dual-specificity phosphatase domain (DSPD, exons 3–4). Missense mutations in DSPD (T194I, G279S, Y294N) cause formation of ubiquitin-positive cytoplasmic aggregates (folding mutants targeted for degradation), while CBD mutants (W32G, R108C) re-localize laforin from cytoplasm to both cytoplasm and nucleus, suggesting diminished affinity for polysomes.","method":"Expression of mutant proteins in HeLa cells, subcellular localization by fluorescence microscopy","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single lab, localization experiments with functional inference, multiple mutants tested","pmids":["12019207"],"is_preprint":false},{"year":2003,"finding":"Laforin interacts with EPM2AIP1 (a novel brain-expressed protein); interaction confirmed by yeast two-hybrid screen and co-immunoprecipitation of in vivo-transfected proteins; subcellular co-localization also demonstrated.","method":"Yeast two-hybrid screen, co-immunoprecipitation, subcellular co-localization","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid confirmed by co-IP, single lab, two orthogonal methods","pmids":["12782127"],"is_preprint":false},{"year":2004,"finding":"The cytoplasmic isoform of laforin (laf331, localized to the endoplasmic reticulum) is the disease-relevant isoform: a mutation (c.950insT, Q319fs) specific to this isoform drastically reduces phosphatase activity while maintaining ER localization, establishing that cytoplasmic laforin function is required for disease prevention.","method":"Mutation identification, subcellular localization assay, phosphatase activity assay","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay (phosphatase activity) and localization, single lab","pmids":["14722920"],"is_preprint":false},{"year":2006,"finding":"Laforin acts as a phosphatase for GSK-3β and functions as a repressor in the Wnt signaling pathway; inactivation of Epm2a leads to increased Wnt signaling and lymphomagenesis in an immunocompromised host.","method":"Insertional mutation and epigenetic silencing in TCR transgenic mice, overexpression and shRNA knockdown, tumor growth assays","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined molecular pathway readout (Wnt signaling, GSK-3β phosphatase substrate), single lab","pmids":["16959610"],"is_preprint":false},{"year":2008,"finding":"The two laforin isoforms (laf331 and laf317) interact with each other forming homo- and heterodimers with distinct activities: laf331 homodimer has robust phosphatase activity; laf317 homodimer and laf331–laf317 heterodimer lack phosphatase activity. Laf331 binds glycogen only as a monomer; laf317 cannot bind glycogen. Both isoforms interact with and serve as substrates for the malin ubiquitin ligase, with malin showing higher affinity for laf331. Disease mutations specific to laf331 abolish laf317–laf331 heterodimerization but not laf331 homodimerization, suggesting laf317 can act as a dominant-negative regulator.","method":"In vitro phosphatase assays, glycogen-binding assays, co-immunoprecipitation, overexpression of isoforms","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal in vitro functional assays (phosphatase activity, glycogen binding, Co-IP with malin), single lab but comprehensive mechanistic study","pmids":["18617530"],"is_preprint":false},{"year":2008,"finding":"Mutant laforin proteins encoded by missense mutations and deletions in EPM2A are unstable, insoluble, ubiquitinated, and accumulate in aggresome-like structures; these aggregates exacerbate ER stress and sensitize neuronal cells to apoptosis induced by ER stressors. Chemical chaperone 4-phenylbutyrate increases mutant solubility and reduces ER stress-induced apoptosis.","method":"Transfection of mutant EPM2A constructs in neuronal cell lines, solubility assays, ubiquitination assays, ER stress assays (thapsigargin), apoptosis assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mutants tested with orthogonal cellular assays (solubility, ubiquitination, ER stress, apoptosis), single lab","pmids":["19403557"],"is_preprint":false},{"year":2011,"finding":"Three novel EPM2A splice variants encode five distinct proteins with unique subcellular localizations; these novel isoforms interact with and serve as substrates for malin ubiquitin ligase. Two phosphatase-active isoforms form an inactive heterodimer in vitro, suggesting antagonistic regulation of EPM2A function by alternative splicing.","method":"Ectopic expression in cell lines, subcellular localization, co-immunoprecipitation with malin, in vitro phosphatase assays","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phosphatase assay and Co-IP, multiple isoforms characterized, single lab","pmids":["22036712"],"is_preprint":false},{"year":2014,"finding":"The phosphatase activity of laforin is dispensable for preventing Lafora disease: expression of phosphatase-dead laforin (C265S mutant) in Epm2a−/− mice fully blocks Lafora body formation and restores impaired macroautophagy, indicating the critical pathogenic process is control of abnormal glycogen accumulation through the laforin–malin complex acting on intracellular proteolytic systems, not glycogen dephosphorylation per se.","method":"Transgenic rescue of Epm2a−/− mice with wild-type or C265S phosphatase-dead laforin; histopathology for Lafora bodies; autophagy assays","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis-based transgenic rescue in knockout mice with multiple functional readouts (Lafora body formation, macroautophagy), rigorous controls","pmids":["24430976"],"is_preprint":false},{"year":2018,"finding":"The laforin N163D mutation, found in a slow-progression LD patient, exhibits near wild-type phosphatase activity and protein stability but shows severe impairment in interactions with previously identified laforin binding partners, suggesting protein–protein interaction capacity (not just phosphatase activity) is critical for laforin function.","method":"Recombinant protein expression, phosphatase activity assay, protein stability assay, binding partner interaction assays","journal":"Epilepsy research","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro biochemical characterization with multiple assays; single lab, no replication","pmids":["30041081"],"is_preprint":false},{"year":2025,"finding":"Laforin overexpression paradoxically causes Lafora body formation, occurring independently of laforin's and malin's enzymatic activities, first and dominantly in dorsal root ganglia; the effect is stronger with human laforin expressed in mice (species mismatch) and is time-dependent, revealing a novel biology of laforin in glycogen quality control.","method":"AAV9-mediated overexpression of laforin in mice, histopathology for Lafora bodies in DRG and brain, enzymatic activity mutant analysis","journal":"Neurotherapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo overexpression with enzymatic activity mutants and histological readout, single study, novel finding","pmids":["41825228"],"is_preprint":false},{"year":2025,"finding":"Lithium treatment of Epm2a−/− mice causes glycogen synthase dephosphorylation (activation, opposite to its effect in normal rat brain) and increased Lafora body formation in hearts (100%) and brains (40%) of treated mice, indicating that laforin-malin complex deficiency inverts lithium's effect on glycogen synthase phosphorylation state.","method":"Lithium treatment of Epm2a−/− knockout mice, glycogen synthase phosphorylation assays, Lafora body quantification","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological intervention with biochemical readouts in knockout model, single lab","pmids":["40258565"],"is_preprint":false}],"current_model":"Laforin (EPM2A) is a dual-specificity glucan phosphatase with a carbohydrate-binding domain and a phosphatase domain; it localizes predominantly to the endoplasmic reticulum/cytoplasm and forms homo- and heterodimers with its alternatively spliced isoform (laf317), which acts as a dominant-negative regulator; laforin interacts with the E3 ubiquitin ligase malin to form a complex that controls glycogen structural integrity and promotes clearance of misfolded proteins via the ubiquitin-proteasome and autophagy systems—loss of this complex (not necessarily laforin's phosphatase activity per se) leads to accumulation of hyperphosphorylated, insoluble polyglucosan Lafora bodies, ER stress, neurodegeneration, and epilepsy; laforin also acts as a GSK-3β phosphatase and Wnt signaling repressor with tumor-suppressive functions."},"narrative":{"mechanistic_narrative":"Laforin (EPM2A) is a dual-specificity phosphatase that safeguards glycogen quality control and intracellular proteostasis, with loss of function producing the neurodegenerative epilepsy Lafora disease [PMID:12019206]. The protein is built from a carbohydrate-binding domain and a dual-specificity phosphatase domain, and disease mutations partition into folding/aggregation mutants in the phosphatase domain and localization-altering mutants in the carbohydrate-binding domain [PMID:12019207]. Cytoplasmic/ER-localized laforin is the disease-relevant species, and its function is required to prevent the formation of insoluble Lafora inclusion bodies that accumulate ubiquitin and drive non-apoptotic neurodegeneration, ataxia, and myoclonic seizures [PMID:12019206, PMID:14722920]. Laforin partners with the malin ubiquitin ligase, serving as both an interactor and substrate, and with EPM2AIP1; its activity is further tuned by alternatively spliced isoforms that form homo- and heterodimers, where the catalytically inactive laf317 isoform acts as a dominant-negative regulator and cannot bind glycogen [PMID:12782127, PMID:18617530, PMID:22036712]. Critically, the phosphatase activity itself is dispensable for disease prevention: a phosphatase-dead laforin still blocks Lafora body formation and restores macroautophagy in Epm2a-null mice, establishing that the pathogenic defect is failure of the laforin-malin complex to control abnormal glycogen and engage proteolytic systems rather than loss of glycogen dephosphorylation per se [PMID:24430976]. Consistent with this, the protein-interaction-defective N163D mutant retains near-normal catalytic activity yet causes disease [PMID:30041081]. Beyond glycogen handling, laforin dephosphorylates GSK-3β and represses Wnt signaling, and its inactivation promotes lymphomagenesis, indicating a tumor-suppressive role [PMID:16959610].","teleology":[{"year":2002,"claim":"Establishing that loss of laforin causes the cardinal features of Lafora disease answered whether EPM2A is causally responsible for the neuropathology rather than merely associated with it.","evidence":"Epm2a knockout mouse with histopathology, EEG, and behavioral readouts","pmids":["12019206"],"confidence":"High","gaps":["Did not define the molecular substrate or biochemical mechanism linking phosphatase loss to inclusion-body formation","Mechanism of non-apoptotic neurodegeneration unresolved"]},{"year":2002,"claim":"Resolving the two-domain architecture and how distinct mutations behave clarified that laforin pathology arises through separable defects in carbohydrate binding versus protein folding/degradation.","evidence":"Expression of CBD and DSPD mutants in HeLa cells with fluorescence localization","pmids":["12019207"],"confidence":"Medium","gaps":["Localization-based inference of polysome affinity not biochemically confirmed","Functional consequence of nuclear re-localization unknown"]},{"year":2003,"claim":"Identifying EPM2AIP1 as a direct partner began to place laforin in a protein-interaction network rather than as a solitary enzyme.","evidence":"Yeast two-hybrid screen, co-immunoprecipitation, co-localization","pmids":["12782127"],"confidence":"Medium","gaps":["Functional role of the EPM2AIP1 interaction not established","No reciprocal endogenous validation"]},{"year":2004,"claim":"Pinpointing the ER-localized cytoplasmic isoform as disease-relevant established which laforin pool must retain function to prevent disease.","evidence":"Isoform-specific frameshift mutation with localization and phosphatase activity assays","pmids":["14722920"],"confidence":"Medium","gaps":["Did not test whether activity or localization is the decisive variable in vivo","Single-mutation inference"]},{"year":2006,"claim":"Showing laforin dephosphorylates GSK-3β and represses Wnt extended its role beyond neuropathology to a tumor-suppressive signaling function.","evidence":"Genetic loss-of-function in transgenic mice, overexpression/shRNA, tumor growth assays","pmids":["16959610"],"confidence":"Medium","gaps":["Relationship between Wnt repression and glycogen/Lafora pathology unclear","Single lab, GSK-3β as direct substrate not structurally confirmed"]},{"year":2008,"claim":"Defining isoform dimerization and malin substrate relationships revealed an autoregulatory layer in which an inactive isoform acts as a dominant-negative.","evidence":"In vitro phosphatase and glycogen-binding assays, co-IP with malin, isoform overexpression","pmids":["18617530"],"confidence":"High","gaps":["Physiological abundance and regulation of laf317 in vivo not established","Structural basis of dimerization unresolved"]},{"year":2008,"claim":"Demonstrating that mutant laforins are insoluble, ubiquitinated aggregates that exacerbate ER stress connected loss of function to proteostatic toxicity, and showed chemical chaperones can mitigate it.","evidence":"Mutant transfection in neuronal cells with solubility, ubiquitination, ER stress, and apoptosis assays plus 4-phenylbutyrate rescue","pmids":["19403557"],"confidence":"Medium","gaps":["Overexpression-based aggregation may not reflect endogenous levels","Causal link from ER stress to neurodegeneration in vivo not shown"]},{"year":2011,"claim":"Characterizing additional splice variants as malin substrates that form inactive heterodimers reinforced alternative splicing as an antagonistic regulator of laforin function.","evidence":"Ectopic expression, localization, co-IP with malin, in vitro phosphatase assays","pmids":["22036712"],"confidence":"Medium","gaps":["Endogenous expression and tissue distribution of variants unverified","Functional significance in disease unclear"]},{"year":2014,"claim":"Showing a phosphatase-dead laforin still prevents Lafora bodies and restores autophagy overturned the assumption that glycogen dephosphorylation is the protective activity, refocusing pathogenesis on the laforin-malin complex and proteolytic control.","evidence":"Transgenic rescue of Epm2a-/- mice with WT or C265S laforin, histopathology and autophagy assays","pmids":["24430976"],"confidence":"High","gaps":["The non-catalytic protective activity not molecularly defined","How the complex controls glycogen structure mechanistically unresolved"]},{"year":2018,"claim":"A catalytically intact but interaction-defective patient mutation confirmed that protein-protein interaction capacity, not phosphatase activity, is critical for laforin function.","evidence":"Recombinant N163D protein with phosphatase, stability, and binding-partner assays","pmids":["30041081"],"confidence":"Medium","gaps":["Specific lost interaction(s) driving disease not identified","Single-patient, single-lab characterization"]},{"year":2025,"claim":"Demonstrating that laforin overexpression paradoxically generates Lafora bodies independent of enzymatic activity exposed a dosage-sensitive glycogen quality-control biology not captured by loss-of-function models.","evidence":"AAV9 overexpression in mice with enzymatic mutants and DRG/brain histopathology","pmids":["41825228"],"confidence":"Medium","gaps":["Mechanism of dosage-dependent Lafora body induction unknown","Relevance of species-mismatch effect to human biology unclear"]},{"year":2025,"claim":"Showing lithium's inverted effect on glycogen synthase in Epm2a-null mice linked laforin-malin deficiency to altered control of glycogen synthase phosphorylation state.","evidence":"Lithium treatment of Epm2a-/- mice with glycogen synthase phosphorylation and Lafora body assays","pmids":["40258565"],"confidence":"Medium","gaps":["Direct enzymatic link between laforin and glycogen synthase phosphorylation not established","Mechanism of inversion unresolved"]},{"year":null,"claim":"The non-catalytic molecular activity by which the laforin-malin complex controls glycogen structure and engages autophagy/proteasome systems remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined molecular mechanism for the protective non-phosphatase function","Structural basis of the laforin-malin complex unresolved","Dosage-sensitive and synthase-related effects mechanistically unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,4,5]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,3,5]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3,6]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,3]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,11]}],"complexes":["laforin-malin complex"],"partners":["NHLRC1","EPM2AIP1","GSK3B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"B3EWF7","full_name":"Laforin, isoform 9","aliases":[],"length_aa":344,"mass_kda":35.2,"function":"","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/B3EWF7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EPM2A","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EPM2A","total_profiled":1310},"omim":[{"mim_id":"620681","title":"MYOCLONIC EPILEPSY OF LAFORA 2; MELF2","url":"https://www.omim.org/entry/620681"},{"mim_id":"620511","title":"FLIEDNER-ZWEIER SYNDROME; FZS","url":"https://www.omim.org/entry/620511"},{"mim_id":"616640","title":"EPILEPSY, PROGRESSIVE MYOCLONIC, 10; EPM10","url":"https://www.omim.org/entry/616640"},{"mim_id":"616639","title":"PR DOMAIN-CONTAINING PROTEIN 8; PRDM8","url":"https://www.omim.org/entry/616639"},{"mim_id":"616023","title":"SR-RELATED C-TERMINAL DOMAIN-ASSOCIATED FACTOR 4; SCAF4","url":"https://www.omim.org/entry/616023"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":71.9},{"tissue":"tongue","ntpm":74.2}],"url":"https://www.proteinatlas.org/search/EPM2A"},"hgnc":{"alias_symbol":["LDE","LD"],"prev_symbol":[]},"alphafold":{"accession":"B3EWF7","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/B3EWF7","model_url":"https://alphafold.ebi.ac.uk/files/AF-B3EWF7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-B3EWF7-F1-predicted_aligned_error_v6.png","plddt_mean":34.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EPM2A","jax_strain_url":"https://www.jax.org/strain/search?query=EPM2A"},"sequence":{"accession":"B3EWF7","fasta_url":"https://rest.uniprot.org/uniprotkb/B3EWF7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/B3EWF7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/B3EWF7"}},"corpus_meta":[{"pmid":"12019206","id":"PMC_12019206","title":"Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12019206","citation_count":201,"is_preprint":false},{"pmid":"12543681","id":"PMC_12543681","title":"Efflux pump Lde is associated with fluoroquinolone resistance in Listeria monocytogenes.","date":"2003","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/12543681","citation_count":106,"is_preprint":false},{"pmid":"23567619","id":"PMC_23567619","title":"NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.","date":"2013","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23567619","citation_count":92,"is_preprint":false},{"pmid":"23482671","id":"PMC_23482671","title":"NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.","date":"2013","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23482671","citation_count":86,"is_preprint":false},{"pmid":"19267391","id":"PMC_19267391","title":"Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19267391","citation_count":80,"is_preprint":false},{"pmid":"12019207","id":"PMC_12019207","title":"Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12019207","citation_count":69,"is_preprint":false},{"pmid":"14574458","id":"PMC_14574458","title":"Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.","date":"2003","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14574458","citation_count":61,"is_preprint":false},{"pmid":"11175283","id":"PMC_11175283","title":"Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.","date":"2000","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11175283","citation_count":48,"is_preprint":false},{"pmid":"16959610","id":"PMC_16959610","title":"Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.","date":"2006","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/16959610","citation_count":44,"is_preprint":false},{"pmid":"16134145","id":"PMC_16134145","title":"Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16134145","citation_count":43,"is_preprint":false},{"pmid":"9176792","id":"PMC_9176792","title":"Expression of CD1 and HLA-DR by Langerhans cells (LC) in oral lichenoid drug eruptions (LDE) and idiopathic oral lichen planus (LP).","date":"1997","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9176792","citation_count":36,"is_preprint":false},{"pmid":"20738377","id":"PMC_20738377","title":"Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease.","date":"2010","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/20738377","citation_count":35,"is_preprint":false},{"pmid":"24430976","id":"PMC_24430976","title":"The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24430976","citation_count":34,"is_preprint":false},{"pmid":"12782127","id":"PMC_12782127","title":"Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product.","date":"2003","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/12782127","citation_count":33,"is_preprint":false},{"pmid":"10668720","id":"PMC_10668720","title":"Identification of new and common mutations in the EPM2A gene in Lafora disease.","date":"2000","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10668720","citation_count":33,"is_preprint":false},{"pmid":"11355878","id":"PMC_11355878","title":"Regional and developmental expression of Epm2a gene and its evolutionary conservation.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11355878","citation_count":32,"is_preprint":false},{"pmid":"28756613","id":"PMC_28756613","title":"Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.","date":"2017","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28756613","citation_count":32,"is_preprint":false},{"pmid":"14722920","id":"PMC_14722920","title":"Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/14722920","citation_count":29,"is_preprint":false},{"pmid":"19403557","id":"PMC_19403557","title":"Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19403557","citation_count":24,"is_preprint":false},{"pmid":"29262631","id":"PMC_29262631","title":"Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29262631","citation_count":24,"is_preprint":false},{"pmid":"18573933","id":"PMC_18573933","title":"Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.","date":"2008","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/18573933","citation_count":21,"is_preprint":false},{"pmid":"22943162","id":"PMC_22943162","title":"Expression of efflux pump gene lde in ciprofloxacin-resistant foodborne isolates of Listeria monocytogenes.","date":"2012","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22943162","citation_count":20,"is_preprint":false},{"pmid":"29175550","id":"PMC_29175550","title":"Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/29175550","citation_count":18,"is_preprint":false},{"pmid":"18617530","id":"PMC_18617530","title":"Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18617530","citation_count":18,"is_preprint":false},{"pmid":"10092504","id":"PMC_10092504","title":"Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10092504","citation_count":17,"is_preprint":false},{"pmid":"33812612","id":"PMC_33812612","title":"Cholesterol-rich nanoemulsion (LDE) as a novel drug delivery system to diagnose, delineate, and treat human glioblastoma.","date":"2021","source":"Materials science & engineering. C, Materials for biological applications","url":"https://pubmed.ncbi.nlm.nih.gov/33812612","citation_count":16,"is_preprint":false},{"pmid":"17509003","id":"PMC_17509003","title":"Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation.","date":"2007","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/17509003","citation_count":16,"is_preprint":false},{"pmid":"18311786","id":"PMC_18311786","title":"Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin.","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18311786","citation_count":15,"is_preprint":false},{"pmid":"25246353","id":"PMC_25246353","title":"Late onset Lafora disease and novel EPM2A mutations: breaking paradigms.","date":"2014","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/25246353","citation_count":15,"is_preprint":false},{"pmid":"38796707","id":"PMC_38796707","title":"Gene therapy for Lafora disease in the Epm2a-/- mouse model.","date":"2024","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38796707","citation_count":13,"is_preprint":false},{"pmid":"33960213","id":"PMC_33960213","title":"A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes.","date":"2021","source":"Nanomedicine (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33960213","citation_count":13,"is_preprint":false},{"pmid":"27574708","id":"PMC_27574708","title":"Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A.","date":"2016","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27574708","citation_count":13,"is_preprint":false},{"pmid":"11735300","id":"PMC_11735300","title":"Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.","date":"2001","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/11735300","citation_count":13,"is_preprint":false},{"pmid":"27092952","id":"PMC_27092952","title":"PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study.","date":"2016","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27092952","citation_count":11,"is_preprint":false},{"pmid":"12560877","id":"PMC_12560877","title":"Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.","date":"2003","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12560877","citation_count":11,"is_preprint":false},{"pmid":"11593299","id":"PMC_11593299","title":"In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells.","date":"2001","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/11593299","citation_count":10,"is_preprint":false},{"pmid":"14643920","id":"PMC_14643920","title":"Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters.","date":"2003","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/14643920","citation_count":9,"is_preprint":false},{"pmid":"24266739","id":"PMC_24266739","title":"Formulation and evaluation of cholesterol-rich nanoemulsion (LDE) for drug delivery potential of cholesteryl-maleoyl-5-fluorouracil.","date":"2013","source":"Pharmaceutical development and technology","url":"https://pubmed.ncbi.nlm.nih.gov/24266739","citation_count":8,"is_preprint":false},{"pmid":"22047982","id":"PMC_22047982","title":"Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families.","date":"2011","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/22047982","citation_count":8,"is_preprint":false},{"pmid":"37059210","id":"PMC_37059210","title":"Epm2aR240X knock-in mice present earlier cognitive decline and more epileptic activity than Epm2a-/- mice.","date":"2023","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37059210","citation_count":7,"is_preprint":false},{"pmid":"30041081","id":"PMC_30041081","title":"A novel EPM2A mutation yields a slow progression form of Lafora disease.","date":"2018","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/30041081","citation_count":7,"is_preprint":false},{"pmid":"7714720","id":"PMC_7714720","title":"The metabolism of a series of ester pro-drugs by NCTC 2544 cells, skin homogenate and LDE testskin.","date":"1994","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7714720","citation_count":7,"is_preprint":false},{"pmid":"41169091","id":"PMC_41169091","title":"Advances in gene therapy for Lafora disease: Intravenous recombinant adeno-associated virus-mediated delivery of EPM2A and EPM2B genes.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41169091","citation_count":5,"is_preprint":false},{"pmid":"22036712","id":"PMC_22036712","title":"Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.","date":"2011","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22036712","citation_count":5,"is_preprint":false},{"pmid":"37030589","id":"PMC_37030589","title":"MiR-95-3p/EPM2A/MMP2 contributes to the pathogenesis of severe preeclampsia through the regulation of trophoblast biological behaviour.","date":"2023","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/37030589","citation_count":3,"is_preprint":false},{"pmid":"35257260","id":"PMC_35257260","title":"Novel mutation of EPM2A causes progressive myoclonic epilepsy: a case report.","date":"2022","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/35257260","citation_count":3,"is_preprint":false},{"pmid":"32342326","id":"PMC_32342326","title":"A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease.","date":"2020","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/32342326","citation_count":3,"is_preprint":false},{"pmid":"38671015","id":"PMC_38671015","title":"Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38671015","citation_count":2,"is_preprint":false},{"pmid":"38168354","id":"PMC_38168354","title":"Gene replacement therapy for Lafora disease in the Epm2a  mouse model.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38168354","citation_count":1,"is_preprint":false},{"pmid":"36199693","id":"PMC_36199693","title":"EPM2A acts as a protective factor in prostate cancer, evidence from a real-world patient cohort.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36199693","citation_count":1,"is_preprint":false},{"pmid":"34733372","id":"PMC_34733372","title":"A novel deletion mutation in EPM2A underlies progressive myoclonic epilepsy (Lafora body disease) in a Pakistani family.","date":"2021","source":"Neurology Asia","url":"https://pubmed.ncbi.nlm.nih.gov/34733372","citation_count":1,"is_preprint":false},{"pmid":"41825228","id":"PMC_41825228","title":"Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.","date":"2026","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/41825228","citation_count":1,"is_preprint":false},{"pmid":"39558147","id":"PMC_39558147","title":"Identification of biallelic intronic EPM2A mutations in a Lafora disease kindred.","date":"2024","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39558147","citation_count":0,"is_preprint":false},{"pmid":"40258565","id":"PMC_40258565","title":"Lithium exacerbates Lafora body formation in the Epm2a-/- Lafora disease mouse model.","date":"2025","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/40258565","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.23.650182","title":"Neuronal Hyperexcitability: A Key to Unravelling Hippocampal Synaptic Dysfunctions in Lafora Disease","date":"2025-04-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.23.650182","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27243,"output_tokens":3108,"usd":0.064174,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10589,"output_tokens":3713,"usd":0.072885,"stage2_stop_reason":"end_turn"},"total_usd":0.137059,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Laforin (EPM2A gene product) is a dual-specificity phosphatase; targeted disruption of Epm2a in mice causes formation of Lafora inclusion bodies (positive for ubiquitin and advanced glycation end-products in neurons), widespread neurodegeneration via a non-apoptotic mechanism (swelling of ER, Golgi, mitochondria without apoptotic bodies or DNA fragmentation), ataxia, spontaneous myoclonic seizures, and EEG epileptiform activity.\",\n      \"method\": \"Epm2a knockout mouse model (gene targeting), histopathology, EEG, behavioral testing\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout mouse with multiple orthogonal phenotypic readouts (histology, EEG, behavior), replicated across tissues\",\n      \"pmids\": [\"12019206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Laforin contains two functional domains: a carbohydrate-binding domain (CBD, exon 1) and a dual-specificity phosphatase domain (DSPD, exons 3–4). Missense mutations in DSPD (T194I, G279S, Y294N) cause formation of ubiquitin-positive cytoplasmic aggregates (folding mutants targeted for degradation), while CBD mutants (W32G, R108C) re-localize laforin from cytoplasm to both cytoplasm and nucleus, suggesting diminished affinity for polysomes.\",\n      \"method\": \"Expression of mutant proteins in HeLa cells, subcellular localization by fluorescence microscopy\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single lab, localization experiments with functional inference, multiple mutants tested\",\n      \"pmids\": [\"12019207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Laforin interacts with EPM2AIP1 (a novel brain-expressed protein); interaction confirmed by yeast two-hybrid screen and co-immunoprecipitation of in vivo-transfected proteins; subcellular co-localization also demonstrated.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, subcellular co-localization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid confirmed by co-IP, single lab, two orthogonal methods\",\n      \"pmids\": [\"12782127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The cytoplasmic isoform of laforin (laf331, localized to the endoplasmic reticulum) is the disease-relevant isoform: a mutation (c.950insT, Q319fs) specific to this isoform drastically reduces phosphatase activity while maintaining ER localization, establishing that cytoplasmic laforin function is required for disease prevention.\",\n      \"method\": \"Mutation identification, subcellular localization assay, phosphatase activity assay\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay (phosphatase activity) and localization, single lab\",\n      \"pmids\": [\"14722920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Laforin acts as a phosphatase for GSK-3β and functions as a repressor in the Wnt signaling pathway; inactivation of Epm2a leads to increased Wnt signaling and lymphomagenesis in an immunocompromised host.\",\n      \"method\": \"Insertional mutation and epigenetic silencing in TCR transgenic mice, overexpression and shRNA knockdown, tumor growth assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined molecular pathway readout (Wnt signaling, GSK-3β phosphatase substrate), single lab\",\n      \"pmids\": [\"16959610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The two laforin isoforms (laf331 and laf317) interact with each other forming homo- and heterodimers with distinct activities: laf331 homodimer has robust phosphatase activity; laf317 homodimer and laf331–laf317 heterodimer lack phosphatase activity. Laf331 binds glycogen only as a monomer; laf317 cannot bind glycogen. Both isoforms interact with and serve as substrates for the malin ubiquitin ligase, with malin showing higher affinity for laf331. Disease mutations specific to laf331 abolish laf317–laf331 heterodimerization but not laf331 homodimerization, suggesting laf317 can act as a dominant-negative regulator.\",\n      \"method\": \"In vitro phosphatase assays, glycogen-binding assays, co-immunoprecipitation, overexpression of isoforms\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal in vitro functional assays (phosphatase activity, glycogen binding, Co-IP with malin), single lab but comprehensive mechanistic study\",\n      \"pmids\": [\"18617530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mutant laforin proteins encoded by missense mutations and deletions in EPM2A are unstable, insoluble, ubiquitinated, and accumulate in aggresome-like structures; these aggregates exacerbate ER stress and sensitize neuronal cells to apoptosis induced by ER stressors. Chemical chaperone 4-phenylbutyrate increases mutant solubility and reduces ER stress-induced apoptosis.\",\n      \"method\": \"Transfection of mutant EPM2A constructs in neuronal cell lines, solubility assays, ubiquitination assays, ER stress assays (thapsigargin), apoptosis assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mutants tested with orthogonal cellular assays (solubility, ubiquitination, ER stress, apoptosis), single lab\",\n      \"pmids\": [\"19403557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Three novel EPM2A splice variants encode five distinct proteins with unique subcellular localizations; these novel isoforms interact with and serve as substrates for malin ubiquitin ligase. Two phosphatase-active isoforms form an inactive heterodimer in vitro, suggesting antagonistic regulation of EPM2A function by alternative splicing.\",\n      \"method\": \"Ectopic expression in cell lines, subcellular localization, co-immunoprecipitation with malin, in vitro phosphatase assays\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phosphatase assay and Co-IP, multiple isoforms characterized, single lab\",\n      \"pmids\": [\"22036712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The phosphatase activity of laforin is dispensable for preventing Lafora disease: expression of phosphatase-dead laforin (C265S mutant) in Epm2a−/− mice fully blocks Lafora body formation and restores impaired macroautophagy, indicating the critical pathogenic process is control of abnormal glycogen accumulation through the laforin–malin complex acting on intracellular proteolytic systems, not glycogen dephosphorylation per se.\",\n      \"method\": \"Transgenic rescue of Epm2a−/− mice with wild-type or C265S phosphatase-dead laforin; histopathology for Lafora bodies; autophagy assays\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis-based transgenic rescue in knockout mice with multiple functional readouts (Lafora body formation, macroautophagy), rigorous controls\",\n      \"pmids\": [\"24430976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The laforin N163D mutation, found in a slow-progression LD patient, exhibits near wild-type phosphatase activity and protein stability but shows severe impairment in interactions with previously identified laforin binding partners, suggesting protein–protein interaction capacity (not just phosphatase activity) is critical for laforin function.\",\n      \"method\": \"Recombinant protein expression, phosphatase activity assay, protein stability assay, binding partner interaction assays\",\n      \"journal\": \"Epilepsy research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro biochemical characterization with multiple assays; single lab, no replication\",\n      \"pmids\": [\"30041081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Laforin overexpression paradoxically causes Lafora body formation, occurring independently of laforin's and malin's enzymatic activities, first and dominantly in dorsal root ganglia; the effect is stronger with human laforin expressed in mice (species mismatch) and is time-dependent, revealing a novel biology of laforin in glycogen quality control.\",\n      \"method\": \"AAV9-mediated overexpression of laforin in mice, histopathology for Lafora bodies in DRG and brain, enzymatic activity mutant analysis\",\n      \"journal\": \"Neurotherapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo overexpression with enzymatic activity mutants and histological readout, single study, novel finding\",\n      \"pmids\": [\"41825228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Lithium treatment of Epm2a−/− mice causes glycogen synthase dephosphorylation (activation, opposite to its effect in normal rat brain) and increased Lafora body formation in hearts (100%) and brains (40%) of treated mice, indicating that laforin-malin complex deficiency inverts lithium's effect on glycogen synthase phosphorylation state.\",\n      \"method\": \"Lithium treatment of Epm2a−/− knockout mice, glycogen synthase phosphorylation assays, Lafora body quantification\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological intervention with biochemical readouts in knockout model, single lab\",\n      \"pmids\": [\"40258565\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Laforin (EPM2A) is a dual-specificity glucan phosphatase with a carbohydrate-binding domain and a phosphatase domain; it localizes predominantly to the endoplasmic reticulum/cytoplasm and forms homo- and heterodimers with its alternatively spliced isoform (laf317), which acts as a dominant-negative regulator; laforin interacts with the E3 ubiquitin ligase malin to form a complex that controls glycogen structural integrity and promotes clearance of misfolded proteins via the ubiquitin-proteasome and autophagy systems—loss of this complex (not necessarily laforin's phosphatase activity per se) leads to accumulation of hyperphosphorylated, insoluble polyglucosan Lafora bodies, ER stress, neurodegeneration, and epilepsy; laforin also acts as a GSK-3β phosphatase and Wnt signaling repressor with tumor-suppressive functions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Laforin (EPM2A) is a dual-specificity phosphatase that safeguards glycogen quality control and intracellular proteostasis, with loss of function producing the neurodegenerative epilepsy Lafora disease [#0]. The protein is built from a carbohydrate-binding domain and a dual-specificity phosphatase domain, and disease mutations partition into folding/aggregation mutants in the phosphatase domain and localization-altering mutants in the carbohydrate-binding domain [#1]. Cytoplasmic/ER-localized laforin is the disease-relevant species, and its function is required to prevent the formation of insoluble Lafora inclusion bodies that accumulate ubiquitin and drive non-apoptotic neurodegeneration, ataxia, and myoclonic seizures [#0, #3]. Laforin partners with the malin ubiquitin ligase, serving as both an interactor and substrate, and with EPM2AIP1; its activity is further tuned by alternatively spliced isoforms that form homo- and heterodimers, where the catalytically inactive laf317 isoform acts as a dominant-negative regulator and cannot bind glycogen [#2, #5, #7]. Critically, the phosphatase activity itself is dispensable for disease prevention: a phosphatase-dead laforin still blocks Lafora body formation and restores macroautophagy in Epm2a-null mice, establishing that the pathogenic defect is failure of the laforin-malin complex to control abnormal glycogen and engage proteolytic systems rather than loss of glycogen dephosphorylation per se [#8]. Consistent with this, the protein-interaction-defective N163D mutant retains near-normal catalytic activity yet causes disease [#9]. Beyond glycogen handling, laforin dephosphorylates GSK-3\\u03b2 and represses Wnt signaling, and its inactivation promotes lymphomagenesis, indicating a tumor-suppressive role [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Establishing that loss of laforin causes the cardinal features of Lafora disease answered whether EPM2A is causally responsible for the neuropathology rather than merely associated with it.\",\n      \"evidence\": \"Epm2a knockout mouse with histopathology, EEG, and behavioral readouts\",\n      \"pmids\": [\"12019206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular substrate or biochemical mechanism linking phosphatase loss to inclusion-body formation\", \"Mechanism of non-apoptotic neurodegeneration unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolving the two-domain architecture and how distinct mutations behave clarified that laforin pathology arises through separable defects in carbohydrate binding versus protein folding/degradation.\",\n      \"evidence\": \"Expression of CBD and DSPD mutants in HeLa cells with fluorescence localization\",\n      \"pmids\": [\"12019207\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Localization-based inference of polysome affinity not biochemically confirmed\", \"Functional consequence of nuclear re-localization unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying EPM2AIP1 as a direct partner began to place laforin in a protein-interaction network rather than as a solitary enzyme.\",\n      \"evidence\": \"Yeast two-hybrid screen, co-immunoprecipitation, co-localization\",\n      \"pmids\": [\"12782127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of the EPM2AIP1 interaction not established\", \"No reciprocal endogenous validation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Pinpointing the ER-localized cytoplasmic isoform as disease-relevant established which laforin pool must retain function to prevent disease.\",\n      \"evidence\": \"Isoform-specific frameshift mutation with localization and phosphatase activity assays\",\n      \"pmids\": [\"14722920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not test whether activity or localization is the decisive variable in vivo\", \"Single-mutation inference\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showing laforin dephosphorylates GSK-3\\u03b2 and represses Wnt extended its role beyond neuropathology to a tumor-suppressive signaling function.\",\n      \"evidence\": \"Genetic loss-of-function in transgenic mice, overexpression/shRNA, tumor growth assays\",\n      \"pmids\": [\"16959610\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between Wnt repression and glycogen/Lafora pathology unclear\", \"Single lab, GSK-3\\u03b2 as direct substrate not structurally confirmed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defining isoform dimerization and malin substrate relationships revealed an autoregulatory layer in which an inactive isoform acts as a dominant-negative.\",\n      \"evidence\": \"In vitro phosphatase and glycogen-binding assays, co-IP with malin, isoform overexpression\",\n      \"pmids\": [\"18617530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological abundance and regulation of laf317 in vivo not established\", \"Structural basis of dimerization unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that mutant laforins are insoluble, ubiquitinated aggregates that exacerbate ER stress connected loss of function to proteostatic toxicity, and showed chemical chaperones can mitigate it.\",\n      \"evidence\": \"Mutant transfection in neuronal cells with solubility, ubiquitination, ER stress, and apoptosis assays plus 4-phenylbutyrate rescue\",\n      \"pmids\": [\"19403557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression-based aggregation may not reflect endogenous levels\", \"Causal link from ER stress to neurodegeneration in vivo not shown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Characterizing additional splice variants as malin substrates that form inactive heterodimers reinforced alternative splicing as an antagonistic regulator of laforin function.\",\n      \"evidence\": \"Ectopic expression, localization, co-IP with malin, in vitro phosphatase assays\",\n      \"pmids\": [\"22036712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous expression and tissue distribution of variants unverified\", \"Functional significance in disease unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing a phosphatase-dead laforin still prevents Lafora bodies and restores autophagy overturned the assumption that glycogen dephosphorylation is the protective activity, refocusing pathogenesis on the laforin-malin complex and proteolytic control.\",\n      \"evidence\": \"Transgenic rescue of Epm2a-/- mice with WT or C265S laforin, histopathology and autophagy assays\",\n      \"pmids\": [\"24430976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The non-catalytic protective activity not molecularly defined\", \"How the complex controls glycogen structure mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A catalytically intact but interaction-defective patient mutation confirmed that protein-protein interaction capacity, not phosphatase activity, is critical for laforin function.\",\n      \"evidence\": \"Recombinant N163D protein with phosphatase, stability, and binding-partner assays\",\n      \"pmids\": [\"30041081\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific lost interaction(s) driving disease not identified\", \"Single-patient, single-lab characterization\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating that laforin overexpression paradoxically generates Lafora bodies independent of enzymatic activity exposed a dosage-sensitive glycogen quality-control biology not captured by loss-of-function models.\",\n      \"evidence\": \"AAV9 overexpression in mice with enzymatic mutants and DRG/brain histopathology\",\n      \"pmids\": [\"41825228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of dosage-dependent Lafora body induction unknown\", \"Relevance of species-mismatch effect to human biology unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showing lithium's inverted effect on glycogen synthase in Epm2a-null mice linked laforin-malin deficiency to altered control of glycogen synthase phosphorylation state.\",\n      \"evidence\": \"Lithium treatment of Epm2a-/- mice with glycogen synthase phosphorylation and Lafora body assays\",\n      \"pmids\": [\"40258565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic link between laforin and glycogen synthase phosphorylation not established\", \"Mechanism of inversion unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The non-catalytic molecular activity by which the laforin-malin complex controls glycogen structure and engages autophagy/proteasome systems remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined molecular mechanism for the protective non-phosphatase function\", \"Structural basis of the laforin-malin complex unresolved\", \"Dosage-sensitive and synthase-related effects mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 4, 5]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 11]}\n    ],\n    \"complexes\": [\"laforin-malin complex\"],\n    \"partners\": [\"NHLRC1\", \"EPM2AIP1\", \"GSK3B\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":7,"faith_total":7,"faith_pct":100.0}}